Wimmer Associates 1 LLC Trims Stake in Novo Nordisk A/S (NYSE:NVO)

Wimmer Associates 1 LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 26.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,785 shares of the company’s stock after selling 1,690 shares during the quarter. Wimmer Associates 1 LLC’s holdings in Novo Nordisk A/S were worth $412,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after acquiring an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC increased its holdings in Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after buying an additional 30,420 shares during the period. Clear Creek Financial Management LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $450,000. DSM Capital Partners LLC increased its holdings in Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after buying an additional 286,912 shares during the period. Finally, Patrick M Sweeney & Associates Inc. increased its holdings in Novo Nordisk A/S by 81.2% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company’s stock valued at $960,000 after buying an additional 5,000 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 2.7%

NYSE:NVO opened at $64.35 on Monday. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The firm has a fifty day simple moving average of $67.31 and a 200-day simple moving average of $84.19. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $288.75 billion, a P/E ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

NVO has been the topic of several research reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.